Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
Latest Information Update: 04 Feb 2025
At a glance
- Drugs PGT 121 (Primary) ; TMB-380 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 30 Jan 2025 Planned End Date changed from 30 Nov 2027 to 30 Jun 2028.
- 30 Jan 2025 Planned primary completion date changed from 31 May 2026 to 31 Dec 2027.
- 30 Jan 2025 Planned initiation date changed from 1 Nov 2024 to 1 Jun 2025.